cisplatin + gemcitabine + ifosfamide + vinorelbine

This drug is a chemotherapy combination consisting of four cytotoxic agents used primarily in cancer treatment. It combines: - **Cisplatin**: A platinum-based alkylating agent that forms DNA crosslinks, leading to apoptosis of rapidly dividing cancer cells. - **Gemcitabine**: A nucleoside analog that inhibits DNA synthesis by incorporation into DNA and inhibition of ribonucleotide reductase. - **Ifosfamide**: An alkylating agent that causes DNA crosslinking and strand breaks, disrupting cancer cell replication. - **Vinorelbine**: A vinca alkaloid microtubule inhibitor that disrupts mitotic spindle formation, preventing cell division. The combination leverages multiple mechanisms to target cancer cells at different points in the cell cycle, enhancing antitumor efficacy. Such multi-agent regimens are used for various advanced solid tumors including lung cancers, bladder cancer, and others. Administration is intravenous with careful monitoring due to potential toxicities such as myelosuppression, nephrotoxicity (cisplatin), neurotoxicity (vinorelbine), hemorrhagic cystitis (ifosfamide), and others.